BR112014004522A2 - moduladores de pde10 - Google Patents
moduladores de pde10Info
- Publication number
- BR112014004522A2 BR112014004522A2 BR112014004522A BR112014004522A BR112014004522A2 BR 112014004522 A2 BR112014004522 A2 BR 112014004522A2 BR 112014004522 A BR112014004522 A BR 112014004522A BR 112014004522 A BR112014004522 A BR 112014004522A BR 112014004522 A2 BR112014004522 A2 BR 112014004522A2
- Authority
- BR
- Brazil
- Prior art keywords
- pde10
- modulators
- pde10 modulators
- compounds
- medicines
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D233/90—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/10—Spiro-condensed systems
- C07D491/107—Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Psychiatry (AREA)
- Diabetes (AREA)
- Psychology (AREA)
- Endocrinology (AREA)
- Addiction (AREA)
- Obesity (AREA)
- Vascular Medicine (AREA)
- Emergency Medicine (AREA)
- Urology & Nephrology (AREA)
- Heart & Thoracic Surgery (AREA)
- Hematology (AREA)
- Cardiology (AREA)
- Hospice & Palliative Care (AREA)
- Pain & Pain Management (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
resumo patente de invenção: "moduladores de pde10". a presente invenção refere-se a compostos de fórmula (i) i em que r1, r2, r3, r5, w, x, x1, y, y1, z e z1 são como definidos na descrição e nas reivindicações, bem como os sais fisiologicamente aceitáveis dos mesmos. estes compostos inibem pde10a e podem ser usados como medicamentos.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP11180135A EP2574607A1 (en) | 2011-09-06 | 2011-09-06 | PDE10 modulators |
PCT/EP2012/067047 WO2013034506A1 (en) | 2011-09-06 | 2012-09-03 | Pde10 modulators |
Publications (1)
Publication Number | Publication Date |
---|---|
BR112014004522A2 true BR112014004522A2 (pt) | 2017-06-13 |
Family
ID=46832363
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR112014004522A BR112014004522A2 (pt) | 2011-09-06 | 2012-09-03 | moduladores de pde10 |
Country Status (14)
Country | Link |
---|---|
US (1) | US8772510B2 (pt) |
EP (2) | EP2574607A1 (pt) |
JP (1) | JP5973576B2 (pt) |
KR (1) | KR101611106B1 (pt) |
CN (1) | CN103781768B (pt) |
AR (1) | AR087771A1 (pt) |
BR (1) | BR112014004522A2 (pt) |
CA (1) | CA2844652C (pt) |
ES (1) | ES2550201T3 (pt) |
HK (1) | HK1195767A1 (pt) |
MX (1) | MX340607B (pt) |
RU (1) | RU2567396C1 (pt) |
TW (1) | TWI434687B (pt) |
WO (1) | WO2013034506A1 (pt) |
Families Citing this family (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2015172196A1 (en) * | 2014-05-13 | 2015-11-19 | Monash University | Heterocyclic compounds and use of same |
JP2021522181A (ja) * | 2018-04-20 | 2021-08-30 | バイエル・アクチエンゲゼルシヤフト | 殺有害生物剤としてのヘテロアリール−トリアゾール化合物及びヘテロアリール−テトラゾール化合物 |
CN110903245B (zh) * | 2018-09-17 | 2022-11-22 | 南京药石科技股份有限公司 | 一种合成1-烷基-2-三氟甲基-5-氨基-1h-咪唑的关键中间体及其制备方法 |
TW202031250A (zh) | 2018-11-06 | 2020-09-01 | 丹麥商H 朗德貝克公司 | 用於治療負性症狀和認知損傷之pde10a抑制劑 |
WO2020094592A1 (en) | 2018-11-06 | 2020-05-14 | H. Lundbeck A/S | Compounds for treating negative symptoms and cognitive impairments |
US20230148601A1 (en) * | 2020-02-18 | 2023-05-18 | Bayer Aktiengesellschaft | Novel heteroaryl-triazole compounds as pesticides |
CN114989103B (zh) * | 2022-06-09 | 2024-07-09 | 杭州科巢生物科技有限公司 | 一种2-甲氧基-3-(1-甲基-1h-1,2,4-三唑-3-基)苯胺的制备方法 |
Family Cites Families (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
TWI260321B (en) | 1999-09-22 | 2006-08-21 | Bristol Myers Squibb Co | Substituted acid derivatives useful as antidiabetic and antiobesity agents and method |
US6861440B2 (en) | 2001-10-26 | 2005-03-01 | Hoffmann-La Roche Inc. | DPP IV inhibitors |
US20070032404A1 (en) | 2003-07-31 | 2007-02-08 | Bayer Pharmaceuticals Corporation | Methods for treating diabetes and related disorders using pde10a inhibitors |
WO2007036734A1 (en) * | 2005-09-29 | 2007-04-05 | Glaxo Group Limited | Pyrazolo[3,4-b]pyridine compound, and its use as a pde4 inhibitor |
WO2008042282A2 (en) * | 2006-09-28 | 2008-04-10 | Exelixis, Inc. | Imidazole-4, 5-dicarboxamide derivatives as jak-2 modulators |
AU2009287621B2 (en) * | 2008-09-04 | 2012-09-20 | Mitsubishi Tanabe Pharma Corporation | Tri-substituted pyrimidine compounds and their use as PDE10 inhibitors |
US8685967B2 (en) * | 2009-04-07 | 2014-04-01 | Merck Sharp & Dohme Corp. | Substituted triazolopyridines and analogs thereof |
BR112012006531A2 (pt) | 2009-09-24 | 2016-11-22 | Hoffmann La Roche | derivados de imidazopirimidina ou imidazopiridina como inibidores da fosfodiesterase 10a. |
AR078793A1 (es) * | 2009-10-27 | 2011-12-07 | Orion Corp | Derivados de carboxamidas no esteroidales y acil hidrazona moduladores de receptores androgenicos de tejido selectivo (sarm), composiciones farmaceuticas que los contienen y uso de los mismos en el tratamiento del cancer de prostata entre otros |
-
2011
- 2011-09-06 EP EP11180135A patent/EP2574607A1/en not_active Ceased
-
2012
- 2012-08-30 US US13/598,848 patent/US8772510B2/en active Active
- 2012-09-03 EP EP12758435.7A patent/EP2753604B1/en not_active Not-in-force
- 2012-09-03 CN CN201280043118.1A patent/CN103781768B/zh not_active Expired - Fee Related
- 2012-09-03 RU RU2014110943/04A patent/RU2567396C1/ru not_active IP Right Cessation
- 2012-09-03 JP JP2014528940A patent/JP5973576B2/ja not_active Expired - Fee Related
- 2012-09-03 KR KR1020147008854A patent/KR101611106B1/ko not_active IP Right Cessation
- 2012-09-03 BR BR112014004522A patent/BR112014004522A2/pt unknown
- 2012-09-03 CA CA2844652A patent/CA2844652C/en not_active Expired - Fee Related
- 2012-09-03 MX MX2014002682A patent/MX340607B/es active IP Right Grant
- 2012-09-03 WO PCT/EP2012/067047 patent/WO2013034506A1/en active Application Filing
- 2012-09-03 ES ES12758435.7T patent/ES2550201T3/es active Active
- 2012-09-04 AR ARP120103252A patent/AR087771A1/es unknown
- 2012-09-05 TW TW101132392A patent/TWI434687B/zh not_active IP Right Cessation
-
2014
- 2014-07-08 HK HK14106920.6A patent/HK1195767A1/zh not_active IP Right Cessation
Also Published As
Publication number | Publication date |
---|---|
CA2844652A1 (en) | 2013-03-14 |
CA2844652C (en) | 2016-11-01 |
HK1195767A1 (zh) | 2014-11-21 |
MX2014002682A (es) | 2014-04-14 |
CN103781768B (zh) | 2016-08-17 |
AR087771A1 (es) | 2014-04-16 |
CN103781768A (zh) | 2014-05-07 |
MX340607B (es) | 2016-07-18 |
EP2574607A1 (en) | 2013-04-03 |
ES2550201T3 (es) | 2015-11-05 |
WO2013034506A1 (en) | 2013-03-14 |
EP2753604A1 (en) | 2014-07-16 |
JP2014525467A (ja) | 2014-09-29 |
TW201317227A (zh) | 2013-05-01 |
TWI434687B (zh) | 2014-04-21 |
US20130059833A1 (en) | 2013-03-07 |
RU2567396C1 (ru) | 2015-11-10 |
US8772510B2 (en) | 2014-07-08 |
KR20140069088A (ko) | 2014-06-09 |
JP5973576B2 (ja) | 2016-08-23 |
KR101611106B1 (ko) | 2016-04-08 |
EP2753604B1 (en) | 2015-08-19 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BR112012031343A2 (pt) | compostos de heteroarila contendo nitrogênio | |
BR112014006248A2 (pt) | compostos de triazolopiridina como inibidores de pde10a | |
BR112012024199A2 (pt) | derivados de n-(imidazopirimidin-7-il)-heteroarilamida e seu uso como inibidores de pde10a | |
BR112012017580A2 (pt) | derivados de heteroarila contendo nitrogênio | |
BR112014026828A2 (pt) | compostos de triazolo como inibidores de pde10 | |
BR112014004522A2 (pt) | moduladores de pde10 | |
BR112015004984A2 (pt) | formulações aquosas estáveis de adalimumab | |
BR112015020795A2 (pt) | derivados de pirazol novos | |
BR112015012919A2 (pt) | novos derivados de piridina | |
BR112013031463A2 (pt) | piridina-2-amidas úteis como agonistas de cb2 | |
BR112015013124A2 (pt) | novos derivados de piridina | |
BR112012006531A2 (pt) | derivados de imidazopirimidina ou imidazopiridina como inibidores da fosfodiesterase 10a. | |
BR112014033080A2 (pt) | inibidores do vírus da hepatite c | |
BR112013023876A2 (pt) | derivados de pirroltriazinona como inibidores de pi3k | |
BR112015009600A2 (pt) | piridina-2-amidas úteis como agonistas cb2 | |
BR112015009603A2 (pt) | novos derivados de pirazina | |
BR112014007193A2 (pt) | derivados de pirazoloquinolinona, preparação dos mesmos e uso terapêutico dos mesmos | |
ECSP13012667A (es) | Compuestos de triazolopiridina | |
BR112014028006A2 (pt) | heterociclos de pirrolidino | |
BR112015012825A2 (pt) | piridopirazinas substituídas como inibidores de syk | |
BR112014010047A8 (pt) | novos derivados de pirazina | |
TR201903918T4 (tr) | Bir dağıtım ajanı içeren bileşimler ve bunların hazırlanması. | |
BR112015001207A2 (pt) | derivados de carbamato/ureia | |
BR112014016803A2 (pt) | amidas macrocíclicas como inibidoras de protease | |
BR112015007823A2 (pt) | derivados de ácido hialurônico modificado e uso dos mesmos |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B350 | Update of information on the portal [chapter 15.35 patent gazette] |